CHF27.22
0.07% yesterday
SIX Swiss Exchange, Nov 20, 05:30 pm CET
ISIN
CH0325814116
Symbol
KURN

Kuros Biosciences Stock price

CHF27.24
-4.92 15.30% 1M
+2.36 9.49% 6M
+5.89 27.59% YTD
+2.89 11.87% 1Y
+25.55 1,507.08% 3Y
+25.09 1,166.98% 5Y
-13.65 33.39% 10Y
-3,466.58 99.22% 20Y
SIX Swiss Exchange, Closing price Thu, Nov 20 2025
+0.00 0.00%
ISIN
CH0325814116
Symbol
KURN
Industry

New AI Insights on Kuros Biosciences Insights AI Insights on Kuros Biosciences

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
CHF1.0b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 200.9
P/S
10.6 | 8.2
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
69.5%
Return on Equity
-7.3%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
CHF95.4m | CHF122.4m
EBITDA
CHF1.1m | CHF5.8m
EBIT
CHF-1.7m | CHF3.3m
Net Income
CHF-5.8m | -
Free Cash Flow
CHF-120.0k
Growth (TTM | estimate)
Revenue
93.6% | 60.3%
EBITDA
143.6% | 637.4%
EBIT
68.3% | 2,887.9%
Net Income
34.6% | -
Free Cash Flow
97.3%
Margin (TTM | estimate)
Gross
83.3%
EBITDA
1.2% | 4.7%
EBIT
-1.8%
Net
-6.0% | -
Free Cash Flow
-0.1%
More
EPS
CHF-0.1
FCF per Share
-
Short interest
-
Employees
122
Rev per Employee
CHF630.0k
Show more

Is Kuros Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Kuros Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kuros Biosciences forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kuros Biosciences forecast:

Buy
88%
Hold
13%

Financial data from Kuros Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
95 95
94% 94%
100%
- Direct Costs 16 16
51% 51%
17%
79 79
105% 105%
83%
- Selling and Administrative Expenses 74 74
79% 79%
78%
- Research and Development Expense 6.93 6.93
24% 24%
7%
1.09 1.09
144% 144%
1%
- Depreciation and Amortization 2.76 2.76
1% 1%
3%
EBIT (Operating Income) EBIT -1.66 -1.66
68% 68%
-2%
Net Profit -5.75 -5.75
35% 35%
-6%

In millions CHF.

Don't miss a Thing! We will send you all news about Kuros Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Christopher Fair
Employees 122
Founded 2000
Website kurosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today